In this study we evaluated heterogeneity in body weight and glycaemic responses to the initiation of liraglutide, semaglutide or dulaglutide in real-world clinical practice
A treatment is FSA-eligible if it addresses medical expenses related to a diagnosed health condition and is not solely for personal pleasure or general wellness
However, as with any treatment, its important to understand potential side effects and contraindications
The most commonly reported adverse events in Phase 2 and Phase 3 trials were gastrointestinal in nature, including nausea, diarrhea, vomiting, and constipation
This drug doesnt fix societal problems
Following the results of the SELECT trial, the FDA approved a new indication for Wegovy (semaglutide) in March 2024: to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight